Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 49/51 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 97/103 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Israel - English - Ministry of Health

novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy

Canada - English - Health Canada

novartis pharmaceuticals canada inc - valsartan (sacubitril valsartan sodium hydrate complex); sacubitril (sacubitril valsartan sodium hydrate complex) - tablet - 26mg; 24mg - valsartan (sacubitril valsartan sodium hydrate complex) 26mg; sacubitril (sacubitril valsartan sodium hydrate complex) 24mg - angiotensin ii receptor antagonists

Canada - English - Health Canada

novartis pharmaceuticals canada inc - valsartan (sacubitril valsartan sodium hydrate complex); sacubitril (sacubitril valsartan sodium hydrate complex) - tablet - 51mg; 49mg - valsartan (sacubitril valsartan sodium hydrate complex) 51mg; sacubitril (sacubitril valsartan sodium hydrate complex) 49mg - angiotensin ii receptor antagonists